- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Glycosylated Fibronectin May be Potential Biomarker for Preeclampsia Diagnosis: Study Finds

China: A recent meta-analysis published in BMC Pregnancy and Childbirth confirmed a significant increase in serum glycosylated fibronectin (GlyFn) levels in preeclampsia (PE) and highlighted its high diagnostic accuracy. These findings suggest that GlyFn could be a promising biomarker for PE's screening and diagnosis.
Preeclampsia, characterized by high blood pressure and organ dysfunction during pregnancy, remains a major cause of maternal and neonatal morbidity. Early detection is crucial for effective management, yet current diagnostic methods rely on clinical symptoms that may appear late in the disease process. Identifying reliable biomarkers could enhance early diagnosis and improve outcomes for at-risk pregnant individuals.
Studies have indicated that maternal serum glycosylated fibronectin levels are significantly higher in individuals with preeclampsia than those without the condition. This elevation suggests GlyFn's potential as a novel biomarker for PE screening and diagnosis. Building on this evidence, Rong Zhou, NHC Key Laboratory of Chronobiology, Sichuan University, Chengdu, China, and colleagues seek to assess GlyFn levels in maternal serum and determine their diagnostic accuracy in detecting PE.
For this purpose, the researchers conducted a systematic literature search across PubMed, EMBASE, Web of Science, and the Cochrane Library until January 15, 2024. Study quality was assessed using the Newcastle-Ottawa Scale and the QUADAS-2 tool. Heterogeneity was analyzed using I² statistics. Standardized mean differences with 95% confidence intervals were calculated to compare maternal serum GlyFn levels between PE and controls. Sensitivity, subgroup analyses, and publication bias assessments ensured result reliability. Diagnostic accuracy was evaluated using pooled sensitivity, specificity, and the area under the summary receiver operating characteristic curve.
Key Findings
- The meta-analysis included 11 studies assessing maternal serum GlyFn levels in preeclampsia.
- GlyFn levels were significantly higher in the PE group compared to the control group (SMD = 1.08).
- Heterogeneity was observed, potentially due to detection and study design variations.
- The pooled sensitivity and specificity of GlyFn for diagnosing PE were 0.81 and 0.80, respectively.
- The overall diagnostic accuracy, measured by the area under the curve, was 0.90.
In conclusion, the meta-analysis confirmed that maternal serum GlyFn levels are significantly elevated in preeclampsia and demonstrate high diagnostic accuracy, highlighting its potential as a reliable biomarker for early detection.
The researchers suggest, that "incorporating GlyFn into screening strategies could offer a faster, more accurate, and cost-effective approach to diagnosing PE, ultimately benefiting maternal and fetal health." However, they stress the need for further large-scale, longitudinal studies to refine diagnostic thresholds and validate clinical utility for routine practice.
Reference:
Liao, L., Liu, M., Yin, Y. et al. Glycosylated fibronectin in preeclampsia: a systematic review and meta-analysis. BMC Pregnancy Childbirth 25, 228 (2025). https://doi.org/10.1186/s12884-025-07243-6
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751